Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb's all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters its position in precision oncology and gives it a lead asset that could ...
Get ready for your aha moment: Every weekday, host Meghna Chakrabarti pierces your news bubble to expose the whole story. Getting answers to the questions that need to be asked, examining our history ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback